Consequently, DLBCL cell lines with defective p300 proteins are resistant to the anti-growth effects of BCL6 inhibitors, and in these cell lines, HDACi synergize with BCL6 inhibitors for inhibition of DLBCL cell growth [106]. Here, BCL6 is linked to diffuse large B-cell lymphoma.